Lexaria Bioscience (LEXX) Net Income towards Common Stockholders Growth (3y) (2017 - 2026)
Lexaria Bioscience (LEXX) Net Income towards Common Stockholders Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 71.02% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 17.25% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.89% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 37.44% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 62.15% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.56% |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | -5.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -5.90% |
| Feb 28, 2026 | 2.50% |
| Nov 30, 2025 | 42.79% |
| Aug 31, 2025 | 56.59% |
| May 31, 2025 | 53.19% |
| Feb 28, 2025 | 23.72% |
| Nov 30, 2024 | 49.70% |
| Aug 31, 2024 | 56.97% |
| May 31, 2024 | 39.32% |
| Feb 29, 2024 | 51.61% |
| Nov 30, 2023 | 55.00% |
| Aug 31, 2023 | 54.37% |
| May 31, 2023 | 55.54% |
| Feb 28, 2023 | 49.90% |
| Nov 30, 2022 | -24.62% |
| Aug 31, 2022 | -10.82% |
| May 31, 2022 | -26.69% |
| Feb 28, 2022 | 48.00% |
| Nov 30, 2021 | -41.64% |
| Aug 31, 2021 | 1.35% |